Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cosmo announces licensing agreement with Dr. Falk Pharma for Rifamycin SV MMX
December 2008
SHARING OPTIONS:

LAINATE, Italy—Cosmo Pharmaceuticals SpA recently announced an agreement with Dr. Falk Pharma GmbH for the licensing of Rifamycin SV MMX. The agreement grants Falk an exclusive license for all of Europe (excluding Italy) and Australia. Rifamycin SV MMX is a broad-spectrum, semi-synthetic antibiotic that is not systemically absorbed when taken orally.

Mauro Ajani, CEO of Cosmo, says "I am very proud of this agreement because it formalizes our relationship with one of the most respected European pharmaceutical companies and further validates our innovative MMX technology. Falk is one of the pioneers of the IBD sector and has a very experienced and extensive distribution network in Europe." DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.